4/14/23, 10:41 PM Hypoglycemia - StatPearls - NCBI Bookshelf

Hypoglycemia
Mathew P, Thoppil D.

Continuing Education Activity

Hypoglycemia is often defined by a plasma glucose concentration below 70 mg/dL; however, signs and symptoms may not occur until plasma glucose
concentrations drop below 55 mg/dL. The symptoms of Whipple's triad have been used to describe hypoglycemia since 1938. For the Whipple triad,
the practitioner must first recognize hypoglycemia symptoms, obtain low blood glucose, and finally, demonstrate immediate relief of symptoms by the
correction of the low blood glucose after treatment. This activity reviews the evaluation and management of hypoglycemia and highlights the
interprofessional team's role in educating patients with this condition about follow up care.

Objectives:

Describe the pathophysiology of hypoglycemia.

Explain the diagnostic approach on how to determine that a patient has hypoglycemia.
Review the management options available for hypoglycemia treatment.
Summarize the importance of interprofessional team strategies for improving care coordination and communication to aid in prompt
diagnosis of hypoglycemia and improving outcomes in patients diagnosed with the condition.

Access free multiple choice questions on this topic.

Introduction
Hypoglycemia is often defined by a plasma glucose concentration below 70 mg/dL; however, signs and symptoms may not occur until plasma glucose
concentrations drop below 55 mg/dL. The symptoms of Whipple's triad have been used to describe hypoglycemia since 1938. For Whipple's triad, the
practitioner must first recognize symptoms of hypoglycemia, then obtain low blood glucose, and finally, demonstrate immediate relief of symptoms by
the correction of the low blood glucose with glucose treatment. Glucose is the primary metabolic fuel for the brain under physiologic conditions.
Unlike other tissues of the body, the brain is very limited in supplying its glucose. Expectedly, the brain requires a steady supply of arterial glucose for
adequate metabolic function. Potential complications can arise from an interruption in the glucose supply. As such, protective mechanisms to guard
against low serum blood glucose (hypoglycemia) have evolved in the body. 

During fasting states, serum glucose levels are maintained via gluconeogenesis and glycogenolysis in the liver. Gluconeogenesis is the pathway in
which glucose is generated from non-carbohydrate sources.  These non-carbohydrate sources could be protein, lipids, pyruvate, or lactate. In contrast,
glycogenolysis is the breakdown of glycogen stored into glucose products. Much of glycogenolysis occurs in hepatocytes (liver) and myocytes
(muscle).

Hypoglycemia is most often seen in patients who have diabetes that undergoing pharmacologic intervention. Among this group, patients with type 1
diabetes are three times as likely to experience hypoglycemia than patients with type 2 diabetes when receiving treatment.

Etiology
In patients who do not have diabetes, hypoglycemia is uncommon, but when it occurs, there are a few major causes of hypoglycemia: pharmacologic,
alcohol, critical illness, counter-regulatory hormone deficiencies, and non-islet cell tumors[1].

Most hypoglycemia cases occur in patients with diabetes who are undergoing therapeutic intervention with meglitinides, sulfonylureas, or insulin.
Drugs are the most common cause of hypoglycemia.[2] Metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose co-transporter
2 inhibitors (SGLT-2), and dipeptidyl peptidase-4 (DPP-4) inhibitor use very infrequently will lead to hypoglycemia.Non-diabetic patients with intact
hepatic function will rarely experience fasting hypoglycemia because of preventative counter-regulatory measures. An episode of true hypoglycemia
in a non-diabetic patient might be due to iatrogenic causes such as surreptitious insulin use. Other potential causes of hypoglycemia are critical illness,
alcohol, cortisol deficiency, or malnourishment.

Alcohol inhibits gluconeogenesis in the body but does not affect glycogenolysis. Thus, hypoglycemia occurs after several days of alcohol
consumption, and after glycogen stores are depleted.

For example, in critical illness states, end-stage liver disease, sepsis, starvation, or renal failure, glucose utilization exceeds glucose intake,
glycogenolysis, and/or gluconeogenesis. The result of this imbalance is potentially the reason why hypoglycemia may occur. Counter-regulatory

https://www.ncbi.nlm.nih.gov/books/NBK534841/ 1/6
4/14/23, 10:41 PM Hypoglycemia - StatPearls - NCBI Bookshelf
hormone deficiencies can occur as in states of adrenal insufficiency. Hypoglycemia associated with such deficiencies is rare. Non-islet cell tumors
may also cause hypoglycemia through increased secretion of insulin-like growth factor 2 (IGF-2).[3] IGF-2 increases glucose utilization, which can
lead to hypoglycemia.

Insulinomas are hyperfunctioning islet cell tumors associated with increased insulin secretion. They can be life-threatening and primarily manifest
with fasting morning hypoglycemia. Although these tumors are rare, they should be a consideration in the workup of suspected cases.[4]

Epidemiology
Hypoglycemia is common with type 1 diabetes, particularly in those patients receiving intensive insulin therapy. Severe hypoglycemic events have
reportedly been anywhere between 62 to 320 episodes per 100 patient-years in type 1 diabetes.[5] As opposed to patients who have type 1 diabetes
and require insulin therapy exclusively, patients with type 2 diabetes experience hypoglycemia relatively less frequently compared to patients with
type 1 diabetes. This can be, in part, due to pharmacotherapies that do not induce hypoglycemia like metformin. The incidence of hypoglycemia in
patients with type 2 diabetes has been reportedly approximately 35 episodes for 100 patient-years.[6] There are no reported disparities in incidents
based on gender.

Pathophysiology
The body has inherent counter-regulatory mechanisms to prevent hypoglycemic episodes. All of these counter-regulatory mechanisms include an
interplay of hormones and neural signals to regulate the release of endogenous insulin, to increase hepatic glucose output, and to alter peripheral
glucose utilization. Among the counter-regulatory mechanisms, the regulation of insulin production plays a major role.  Decrease in insulin production
as a response to low serum glucose isn't the body's first line of defense against hypoglycemia. For endogenous glucose production to take place,
particularly hepatic glycogenolysis, low insulin levels are necessary. As plasma glucose levels decline, beta-cell secretion of insulin also decreases,
leading to increased hepatic/renal gluconeogenesis and hepatic glycogenolysis. Glycogenolysis maintains serum glucose levels over 8 to 12 hours until
glycogen stores are depleted. Over time, hepatic gluconeogenesis contributes more to maintaining euglycemia when required.

The decrease in insulin production occurs while the glucose level is in the low-normal range. This serves as a distinctive feature compared to other
counter-regulatory measures. Additional counter-regulatory measures typically occur once the serum glucose levels decrease beyond the physiologic
range. Among the additional counter-regulatory mechanisms, pancreatic alpha cell secretion of glucagon is the next line of defense against
hypoglycemia. Should increased glucagon fail to achieve euglycemia, adrenomedullary epinephrine is secreted.[7] All three counter-regulatory
measures occur in the acute stage of hypoglycemia.

On occasions the previously mentioned counter-regulatory mechanisms may fail to resolve the hypoglycemia. At this point, further counter-regulatory
measures are employed in the form of growth hormone and cortisol. Both the release of growth hormone and cortisol are seen in prolonged
hypoglycemic state.

History and Physical

The clinical manifestations of hypoglycemia can be classified as either neuroglycopenic or neurogenic. Neuroglycopenic signs and symptoms are
signs and symptoms that result from direct central nervous system (CNS) deprivation of glucose. These include behavioral changes, confusion,
fatigue, seizure, coma, and potential death if not immediately corrected. Neurogenic signs and symptoms can either be adrenergic (including tremors,
palpitations, anxiety) or cholinergic (including hunger, diaphoresis, paresthesias). Neurogenic symptoms and signs arise from sympathoadrenal
involvement (either norepinephrine or acetylcholine release) in response to perceived hypoglycemia. 

A detailed history is essential in evaluating hypoglycemia. Pertinent issues that should be addressed while taking a patient's history include:

A detailed medication history

History of alcohol and/or drug use
History of psychiatric disorders
Personal or family history of diabetes mellitus or multiple endocrine neoplasia syndromes (MEN)
Unintentional weight changes
Changes in medication
Consideration of acute kidney injury or renal failure
Symptoms of different hormone deficiencies.
Timing of the hypoglycemic episode relative to meals or exercise.

https://www.ncbi.nlm.nih.gov/books/NBK534841/ 2/6
4/14/23, 10:41 PM Hypoglycemia - StatPearls - NCBI Bookshelf

There is no agreed-upon lab value that defines hypoglycemia. Hypoglycemia is said to be present when the patient has symptoms consistent with
hypoglycemia in addition to a low serum glucose measurement (less than 70 mg/dL). This perspective reflects the idea that hypoglycemia is a clinical
presentation coupled with a lab finding of low serum glucose rather than a pure chemistry finding. Typically neurogenic and neuroglycopenic
symptoms of hypoglycemia occur at a glucose level of or below 50 to 55 mg/dL, but this threshold can vary from individual to individual.

Patients who have diabetes can present with symptoms of hypoglycemia at relatively higher serum glucose levels. The chronic hyperglycemia alters
the "set point" in which neuroglycopenic/neurogenic symptoms become apparent. This phenomenon is referred to as "pseudohypoglycemia"
[8] because the serum glucose may be within normal range despite symptom presentation.

Evaluation
As previously mentioned, documentation of Whipple’s triad is a potential indicator of hypoglycemia, and any initial laboratory evaluation should
confirm hypoglycemia. Other pertinent labs to consider include insulin, proinsulin, and C-peptide levels during any episode of suspected
hypoglycemia. If C-peptide levels are low in the presence of high insulin levels, the patient has received exogenous insulin. The pro-form of insulin
created within the body is attached to C-peptide. The body cleaves C-peptide from the pro-form of the molecule to create active insulin. Elevated C-
peptide levels together with insulin levels can be seen with secretagogue agents such as sulfonylureas or insulin secretagogues since both classes of
agents stimulate endogenous insulin secretion.

Once the use of exogenous insulin administration is ruled out, sources of endogenous hyperinsulinemia need to be considered. Localization is usually
performed via abdominal computed tomography (CT) or with MRI.

Treatment / Management
Identification of a hypoglycemic patient is critical due to potential adverse effects, including coma and/or death. Severe hypoglycemia can be treated
with intravenous (IV) dextrose followed by infusion of glucose. For conscious patients able to take oral (PO) medications, readily absorbable
carbohydrate sources (such as fruit juice) should be given. For patients unable to take oral agents, glucagon should be administered. Glucagon can be
given intramusularly, or intranasally with the newest available formulations.[9][10] Once the patient is more awake, a complex carbohydrate food
source should be given to achieve sustained euglycemia. More frequent blood glucose monitoring should occur to rule out further drops in blood
sugar.

Nonpharmacological management of recurrent hypoglycemia involves patient education and lifestyle changes. Some patients are unaware of the
serious ramifications of persistent hypoglycemia. As such, patients should be educated on the importance of routine blood glucose monitoring as well
as on the identification of the individual's symptoms of hypoglycemia. If lifestyle changes are not effective in preventing further episodes, then
pharmacologic intervention should be modified. Patients should be advised to wear a medical alert bracelet or necklace and to also carry a glucose
source like gel, candy, or tablets on their purse in case symptoms arise. In the outpatient setting, reviewing blood sugar logs and food logs may help
identify problem areas for the patient.

Glycemic control has been an important aspect of medical management due to the association between glycated hemoglobin levels and cardiovascular
events in diabetes mellitus type 2 patients. In the 2008 ACCORD trial, it was determined that intensive therapy (defined as a goal hemoglobin A1C
less than 6.0%) did not significantly reduce major cardiovascular events and was associated with increased mortality and risk for hypoglycemia.[11]
However, it should be noted that the intensive therapy group had proportionally more participants using rosiglitazone compared to the standard
therapy group (91.2% versus 57.5%), thus possibly contributing to an increased incidence of cardiovascular events in the intensive therapy group.

The 2009 VADT study additionally studied the effect of intensive blood glucose control in a sample of 1791 veterans with poorly controlled diabetes
mellitus type 2. More rigid glycemic control did not appear to have a significant effect on cardiovascular outcomes, although it did improve
microalbuminuria compared to the standard therapy arm.[12] However, the results cannot be extrapolated to females since 97% of the study
participants were male. Besides, there was a significant dropout (approximately 15%), limiting statistical power.

Regarding endogenous sources of insulin, insulinomas are often managed surgically. Evidence of an insulinoma should prompt workup or
investigative effort into potential multiple endocrine neoplasia (MEN) disorders.

Differential Diagnosis
If hypoglycemia is confirmed, the focus should be on correcting the hypoglycemia and identifying the underlying cause. In the workup of
hypoglycemia, history should include medication and dietary adherence, medication changes, suspicion for acute kidney injury, or
intentional/unintentional weight changes, especially weight loss.

https://www.ncbi.nlm.nih.gov/books/NBK534841/ 3/6
4/14/23, 10:41 PM Hypoglycemia - StatPearls - NCBI Bookshelf

Prognosis
Severe insulin reactions may be proven fatal, so it is essential to contact EMS immediately when an individual is disoriented or unconscious. The
patients with diabetes should also reach out to their clinicians if they begin to experience frequent hypoglycemic episodes, as they may need to have
adjustments made to their medication regimen, meal plans, or even their exercise/activity regimen. Non-diabetic individuals who show signs or
symptoms of hypoglycemia should contact their clinician to further evaluate their situation. Severe or prolonged hypoglycemia can be life-threatening,
and in patients with diabetes, there is a correlation with increased mortality. In non-diabetic individuals experiencing reactive hypoglycemia, the
prognosis is good.

Complications
Complications of untreated hypoglycemia can lead to serious neurologic consequences, like seizures, brain damage and even death.

Consultations
Most cases of hypoglycemia can be managed conservatively. Recurrent episodes of hypoglycemia with no apparent or obvious cause may warrant
specialty consultation with an endocrinologist. Consultation with a diabetic educator may also be beneficial for the long-term management of diabetes
and hypoglycemia.

Deterrence and Patient Education

Patient education remains a pivotal component in the prevention of hypoglycemic episodes. Focus on preventing hypoglycemia should include patient
education on signs and symptoms that constitute hypoglycemia and early recognition of these signs and symptoms. Patients may also need counseling
on meal plans and exercise to manage their condition better.

Pearls and Other Issues

Hypoglycemia in non-diabetic patients is uncommon. When it does occur, a critical illness[13], sustained alcohol use[14], malnutrition, and exogenous
medications should be considered. Tumors may be a cause of hypoglycemia but are rare.[15]

Hypoglycemia is relatively common in neonates, particularly in mothers with uncontrolled diabetes. A 2017 study performed in Israel showed that 559
neonates out of 3595 live births were observed to have a glucose level of less than 47 mg/dL.[16] Gestational glucose intolerance in the mother is
usually attributed to the presence of human placental lactogen. Pregnant women with impaired glucose tolerance not responsive to diet or exercise
should be started on insulin. Insulin does not cross the placenta, although the fetus will be exposed to maternal hyperglycemia. Since the fetal
pancreatic islet cells produce insulin starting at 10 weeks gestation, the fetal pancreas is capable of responding to hyperglycemia. Upon delivery, the
newborn pancreas continues to secrete insulin, although maternal hyperglycemia is withdrawn. Subsequently, the neonate’s glucose will decrease,
resulting in an insulin-glucose imbalance and hypoglycemia.

Enhancing Healthcare Team Outcomes

An interprofessional approach to hypoglycemia is recommended. Adequate interprofessional measures to minimize hypoglycemic events involve
participation and effective communication between the primary care physicians, physician assistants, nurse practitioners, endocrinologists, diabetes
educators, pharmacists, specialty-trained diabetes nurses, the patient's family, nutritionists and/or dieticians, and the patient. The cornerstone of this
management is the patient.

Patient education should address the importance of relatively detailed documentation regarding blood glucose levels, timing, units of insulin
administered, and any pertinent notes such as increased/decreased food intake or exercise level relative to blood glucose measurements. Such
documentation allows a primary care physician or an endocrinologist to make appropriate adjustments to diabetic medication therapy for optimizing
blood glucose levels. Stability of blood glucose levels can be obtained with consistent dietary and exercise habits in addition to the appropriate timing
of insulin therapy to avoid drastic spikes or dips in blood glucose levels. Hospitalized patients with newly diagnosed diabetes can be taught by the
nurse diabetic educator how to do the insulin administration and self-injections while in the hospital. The educator should collaborate with the
clinician managing the case so that appropriate patient education is achieved before discharge. Discussions with the patient and pharmacist will help
decide the best medications to achieve safe glycemic control. Group education classes and local event planning can help patients with diabetes to learn
and grow their knowledge among themselves and other members of the household.

https://www.ncbi.nlm.nih.gov/books/NBK534841/ 4/6
4/14/23, 10:41 PM Hypoglycemia - StatPearls - NCBI Bookshelf
Non-adherence to medication or diet is the most common cause of treatment failure. Patients should monitor themselves for signs or symptoms of
hypoglycemia and always have sources of glucose (for example, hard candy, fruit juice) immediately available. Developing programs to educate
healthcare staff has also been shown to provide better outcomes. Teaming up with local pharmacies or grocery stores can help overcome some of the
barriers often encountered by patients with diabetes.

Patients should be advised to have fairly consistent exercise and dietary habits to avoid drastic changes in hour-to-hour blood glucose measurements.

With an interprofessional approach to hypoglycemia, outcomes will be optimized, leading to better patient quality of life. [Level 5]

Review Questions
Access free multiple choice questions on this topic.
Comment on this article.

References
1. Koch CA, Petersenn S. Black swans - neuroendocrine tumors of rare locations. Rev Endocr Metab Disord. 2018 Jun;19(2):111-121. [PubMed:
30341705]
2. Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am. 1999 Sep;28(3):555-77. [PubMed: 10500931]
3. Daughaday WH. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I. J Clin Endocrinol Metab. 2007 May;92(5):1616.
[PubMed: 17483375]
4. Dardano A, Daniele G, Lupi R, Napoli N, Campani D, Boggi U, Del Prato S, Miccoli R. Nesidioblastosis and Insulinoma: A Rare Coexistence and
a Therapeutic Challenge. Front Endocrinol (Lausanne). 2020;11:10. [PMC free article: PMC6996476] [PubMed: 32047477]
5. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2010 Sep;39(3):641-54. [PMC free article: PMC2923455]
[PubMed: 20723825]
6. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP., DARTS/MEMO Collaboration. Frequency
and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005 Jun;22(6):749-55.
[PubMed: 15910627]
7. Cryer PE. Hypoglycemia in diabetes: pathophysiological mechanisms and diurnal variation. Prog Brain Res. 2006;153:361-5. [PubMed:
16876586]
8. Lee KT, Abadir PM. Failure of Glucose Monitoring in an Individual with Pseudohypoglycemia. J Am Geriatr Soc. 2015 Aug;63(8):1706-8. [PMC
free article: PMC5407681] [PubMed: 26289697]
9. La Sala L, Pontiroli AE. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected
Stable Solutions. Int J Mol Sci. 2021 Sep 30;22(19) [PMC free article: PMC8508740] [PubMed: 34638984]
10. Isaacs D, Clements J, Turco N, Hartman R. Glucagon: Its evolving role in the management of hypoglycemia. Pharmacotherapy. 2021
Jul;41(7):623-633. [PubMed: 33963599]
11. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman
WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2
diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. [PMC free article: PMC4551392] [PubMed: 18539917]
12. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S,
McCarren M, Vitek ME, Henderson WG, Huang GD., VADT Investigators. Glucose control and vascular complications in veterans with type 2
diabetes. N Engl J Med. 2009 Jan 08;360(2):129-39. [PubMed: 19092145]
13. Plečko D, Bennett N, Mårtensson J, Bellomo R. The obesity paradox and hypoglycemia in critically ill patients. Crit Care. 2021 Nov
01;25(1):378. [PMC free article: PMC8559391] [PubMed: 34724956]
14. Shukla L, Reddy S, Kulkarni G, Chand PK, Murthy P. Alcohol Dependence, Hypoglycemia, and Transient Movement Disorders. Prim Care
Companion CNS Disord. 2019 Jan 03;21(1) [PubMed: 30620452]
15. Yadav RS, Pokharel A, Gaire D, Shrestha S, Pokharel A, Pradhan S, Kansakar PBS. Multiple Endocrine Neoplasia Type 1 with Concomitant
Existence of Malignant Insulinoma: A Rare Finding. Case Rep Endocrinol. 2021;2021:8842667. [PMC free article: PMC8337156] [PubMed:
34367700]
16. Bromiker R, Perry A, Kasirer Y, Einav S, Klinger G, Levy-Khademi F. Early neonatal hypoglycemia: incidence of and risk factors. A cohort
study using universal point of care screening. J Matern Fetal Neonatal Med. 2019 Mar;32(5):786-792. [PubMed: 29020813]

https://www.ncbi.nlm.nih.gov/books/NBK534841/ 5/6
4/14/23, 10:41 PM Hypoglycemia - StatPearls - NCBI Bookshelf

Publication Details

Author Information and Affiliations

Authors

Philip Mathew1; Deepu Thoppil2.

Affiliations

1
St. Luke's at Des Peres Hospital
2 Wesley Medical Center

Publication History

Last Update: December 26, 2022.

Copyright
Copyright © 2023, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) (
http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not
required to obtain permission to distribute this article, provided that you credit the author and journal.

Publisher

StatPearls Publishing, Treasure Island (FL)

NLM Citation

Mathew P, Thoppil D. Hypoglycemia. [Updated 2022 Dec 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.

https://www.ncbi.nlm.nih.gov/books/NBK534841/ 6/6